Skip to main
ATOS

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc. is positioned favorably due to its focus on developing proprietary medicines addressing significant unmet medical needs in oncology, particularly with its lead drug, Endoxifen, targeting breast cancer and related conditions. The company's ongoing development of COVID-19 therapies, including inhaled and nasal spray formulations, broadens its market potential and enhances its valuation metrics. Anticipated clinical milestones are expected to serve as strong catalysts for the stock, contributing to a generally positive outlook for investors.

Bears say

Atossa Therapeutics Inc. has reported consistent net losses, amounting to $8.7 million and $8.4 million, accompanied by a recurring earnings per share (EPS) of $(0.07), which fell short of both internal and consensus estimates. The company's financial outlook is hindered by multifaceted risks, including significant balance sheet and liquidity challenges, as well as potential failures in clinical trials to prove the safety and efficacy of its product candidates. Additional concerns involve difficulties in gaining regulatory approvals, securing suitable reimbursement, and facing intense market competition, all of which contribute to a negative sentiment regarding the company's future performance.

Atossa Genetics (ATOS) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.